NasdaqGS - Delayed Quote USD

Pharvaris N.V. (PHVS)

22.10

+1.30

(+6.25%)

At close: 4:00 PM EDT

Key Events

Loading Chart for PHVS

9/21 12:03 PM

DELL

Previous Close 20.80
Open 21.10
Bid 21.34 x 100
Ask 23.25 x 100
Day's Range 21.10 - 23.07
52 Week Range 8.20 - 33.00
Volume 60,953
Avg. Volume 72,965
Market Cap (intraday) 1.211B
Beta (5Y Monthly) --
PE Ratio (TTM) --
EPS (TTM) -2.67
Earnings Date Aug 5, 2024 - Aug 9, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 33.15

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

82

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PHVS

21.21%

S&P 500

11.29%

1-Year Return

PHVS

176.25%

S&P 500

28.71%

3-Year Return

PHVS

3.46%

S&P 500

27.18%

5-Year Return

PHVS

--

S&P 500

36.57%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

22.10

+6.25%

Mkt Cap 1.211B

Industry Biotechnology

KalVista Pharmaceuticals, Inc.

12.01

-3.84%

Mkt Cap 506.682M

Industry Biotechnology

13.82

-1.22%

Mkt Cap 447.635M

Industry Biotechnology

Neumora Therapeutics, Inc.

9.67

+0.94%

Mkt Cap 1.543B

Industry Biotechnology

Spyre Therapeutics, Inc.

37.38

-4.86%

Mkt Cap 1.506B

Industry Biotechnology

IO Biotech, Inc.

1.4300

-0.69%

Mkt Cap 94.21M

Industry Biotechnology

Disc Medicine, Inc.

31.86

+0.06%

Mkt Cap 787.633M

Industry Biotechnology

Prelude Therapeutics Incorporated

4.0000

+3.63%

Mkt Cap 216.303M

Industry Biotechnology

Immunocore Holdings plc

56.01

+0.29%

Mkt Cap 2.793B

Industry Biotechnology

Edgewise Therapeutics, Inc.

17.68

+1.38%

Mkt Cap 1.655B

Industry Biotechnology

71.68

+5.38%

Mkt Cap 4.495B

Industry Biotechnology

Valuation Measures

As of 5/14/2024

Market Cap

1.12B
Enterprise Value

722.04M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

2.89
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-24.78%
Return on Equity (ttm)

-43.52%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-106.26M
Diluted EPS (ttm)

-2.67

Balance Sheet and Cash Flow

Total Cash (mrq)

368.34M
Total Debt/Equity (mrq)

0.05%
Levered Free Cash Flow (ttm)

-50.79M

PHVS does not have Company Insights

VOR Vor Biopharma Inc.

1.7400

+3.57%

EWTX Edgewise Therapeutics, Inc.

17.68

+1.38%

ORIC ORIC Pharmaceuticals, Inc.

9.31

+2.42%

NUVL Nuvalent, Inc.

71.68

+5.38%

IMCR Immunocore Holdings plc

56.01

+0.29%

LABP Landos Biopharma, Inc.

22.30

-0.36%

CGEM Cullinan Therapeutics, Inc.

26.72

+1.29%

FDMT 4D Molecular Therapeutics, Inc.

25.58

-0.66%

DAWN Day One Biopharmaceuticals, Inc.

16.42

-1.20%

LVTX LAVA Therapeutics N.V.

2.8300

-2.08%

BMEA Biomea Fusion, Inc.

13.24

+7.03%

PRAX Praxis Precision Medicines, Inc.

44.00

-4.14%

PCVX Vaxcyte, Inc.

71.63

+6.39%

IKNA Ikena Oncology, Inc.

1.3350

+0.38%

LBPH Longboard Pharmaceuticals, Inc.

21.14

+3.88%

INZY Inozyme Pharma, Inc.

4.6700

+0.86%